COVID-19 IgG, Qualitative by CIA
Also known as: COV19QUALG
Use
The test is used for the qualitative detection of IgG antibodies against the nucleocapsid protein of SARS-CoV-2, which develop in response to natural infection with the virus. These antibodies do not form as a result of vaccination against COVID-19. The test can aid in determining past exposure to the virus but is not recommended for assessing the immune response to vaccination. Negative results do not rule out SARS-CoV-2 infection, and the test should not be used as the sole basis to diagnose or exclude infection or to inform infection status.
Special Instructions
Not provided.
Limitations
The test should not be used for screening donated blood. It is under FDA Emergency Use Authorization and should not be the sole basis used to diagnose or exclude SARS-CoV-2 infection. False-positive results can occur due to past or present infection with non-SARS-CoV-2 strains such as HKU1, NL63, OC43, or 229E. In low prevalence settings, false positives are possible even with a high specificity rate of the test. Follow-up testing with a molecular diagnostic test should be considered for individuals in contact with the virus.
New York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
IgG nucleocapsid antibodies
Protein
LOINC Codes
- 94563-4 - SARS-CoV-2 IgG SerPl Ql IA
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.25 mL
Container
ARUP Standard Transport Tube
Storage Instructions
Refrigerated transport
Causes for Rejection
Grossly hemolyzed, grossly icteric, or severely lipemic specimens. Postmortem specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 1 week |
| Frozen | 1 month |
Other tests from different labs that may be relevant